0000950170-24-037180.txt : 20240327 0000950170-24-037180.hdr.sgml : 20240327 20240327161007 ACCESSION NUMBER: 0000950170-24-037180 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nguyen Alexander Hieu CENTRAL INDEX KEY: 0001850065 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 24790708 MAIL ADDRESS: STREET 1: C/O UNITY BIOTECHNOLOGY, INC. STREET 2: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 416-1192 MAIL ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 4 1 ownership.xml 4 X0508 4 2024-03-26 0001463361 Unity Biotechnology, Inc. UBX 0001850065 Nguyen Alexander Hieu 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 false true false false Chief Legal Officer false Common Stock, $0.0001 par value 2024-03-26 4 A false 20000 0 A 25104 D Stock Option (Right to Buy) 1.62 2024-03-26 4 A false 30000 0 A 2034-03-25 Common Stock 30000 30000 D Represents Restricted Stock Units ("RSUs") one quarter of which vests on March 26, 2025 with the remaining RSUs vesting in equal quarterly installments over a three year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Includes RSUs which vest over time measured from the grant date. The underlying shares vest and become exercisable pursuant to the following schedule: One Fourth of the shares subject to the option vest on March 26, 2025 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. /s/ Alexander Hieu Nguyen 2024-03-27